echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Drugs Articles > Lanzhou High-tech Zone issued 20 "hard core" measures to accelerate the development of the biopharmaceutical industry.

    Lanzhou High-tech Zone issued 20 "hard core" measures to accelerate the development of the biopharmaceutical industry.

    • Last Update: 2020-07-18
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    on June 30, Lanzhou High-tech Zone issued "Several Measures on Speeding up the Development of the Biopharmaceutical Industry", which involves 20 "hard core" measures, which apply to enterprises and institutions registered and taxed in Lanzhou High-tech Zone, have independent legal personality, engage in biopharmaceutical research and development, production and service, and have a probationary period of two yearsin order to support the development of the biopharmaceutical industry, "Measures" will be new investment in biopharmaceutical research and development, production and medical big data, Internet medical and other projects, fixed assets (excluding land) actual investment of 50 million yuan (including) or more, after completion and acceptance in accordance with 10% of the actual amount of investment to give a one-time reward, a single project reward not more than 10 million yuanto set up regional headquarters in Lanzhou High-tech Zone and continue to operate for more than 3 years of the top 100 enterprises, the first 3 years in accordance with the company to pay income tax in the high-tech zone to obtain a portion of 50% of the incentiveat the same time, the Measures will also provide financial and policy support to biopharmaceutical research and development innovation, scientific research achievements in Chinese medicine, medical device development, biopharmaceutical commissioned production, construction of biomedical public platforms, and introduction of biomedical talents, in the field of biopharmaceutical research and development innovation, Lanzhou High-tech Zone to conduct clinical trials in China and the transformation of new drugs in the region, according to its research and development progress in stages to fundEnterprises that have obtained clinical approval of new National Class I drugs (including Chinese and natural medicines, chemicals and biological products) shall be supported at 40% of the actual investment in research and development costs, not exceeding 5 million yuanThe completion of Phase I, II, III clinical trials, respectively, not more than 8 million, 12 million, 20 million yuan to give financial support, a single enterprise annual funding does not exceed 20 million yuanto obtain clinical approval of the national class 2 chemical drugs, 2-5 biological products, 2-6 types of Chinese medicine and natural drugs, according to the actual investment of 40% of the research and development costs, not more than 2 million yuanThe completion of Phase I, II, III clinical trials, respectively, not more than 2 million, 5 million, 10 million yuan to give financial support, a single enterprise annual funding does not exceed 10 million yuan, the non-first generic drugs (Chinese medicine and natural drugs, chemicals, biological products) that have obtained the drug approval number shall be supported at 20% of the actual investment in research and development costs, not exceeding 3 million yuan;Lanzhou High-tech Zone as a gathering place for biopharmaceutical industry, gather to cultivate the leading industry of biopharmaceuticalindustry, relying on the existing development base and Gansu biopharmaceutical resources advantages, and constantly optimize the structure, enhance innovation ability, accelerate the industrial characteristics, scale, cluster development, to build an important base for the development of biopharmaceutical industry in the western regionIn the top 50 list of comprehensive competitiveness of China Biopharmaceutical Industrial Park in 2019, Lanzhou High-tech Zone ranked 47th, which shows the competitiveness of the biopharmaceutical industry in the parkwith the introduction of this Measure, will be conducive to the integration of regional resource advantages, accelerate the simultaneous development of biopharmaceutical-related production equipment, raw materials supply, logistics, sales and service outsourcing upstream and downstream industrial chain enterprisesit is understood that the next step, Lanzhou High-tech Zone will take biomedicine as the main industry, the implementation of bio-pharmaceutical innovative enterprise cultivation action plan, the collection of various elements of resources, the first cultivation, the first support, the formation of biopharmaceutical industry cluster focusing on biopharmaceutical, modern Chinese medicine, biomedical engineering and animal medicine, to create a number of more competitive and influential biopharmaceutical brands.
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.